Urru, S.A.M.; Mayer, F.; Spila Alegiani, S.; Paoloni, F.; Guella, A.; Murru, R.; Bucaneve, G.; Formoso, G.; Racanelli, V.; Ferrarini, I.;
et al. The Importance of Real-World Data in Evaluating the Safety of Biosimilars: A Descriptive Study of Clinical Practice in an Oncohematological Italian Population. Cancers 2024, 16, 3419.
https://doi.org/10.3390/cancers16193419
AMA Style
Urru SAM, Mayer F, Spila Alegiani S, Paoloni F, Guella A, Murru R, Bucaneve G, Formoso G, Racanelli V, Ferrarini I,
et al. The Importance of Real-World Data in Evaluating the Safety of Biosimilars: A Descriptive Study of Clinical Practice in an Oncohematological Italian Population. Cancers. 2024; 16(19):3419.
https://doi.org/10.3390/cancers16193419
Chicago/Turabian Style
Urru, Silvana A. M., Flavia Mayer, Stefania Spila Alegiani, Francesca Paoloni, Anna Guella, Roberta Murru, Giampaolo Bucaneve, Giulio Formoso, Vito Racanelli, Isacco Ferrarini,
and et al. 2024. "The Importance of Real-World Data in Evaluating the Safety of Biosimilars: A Descriptive Study of Clinical Practice in an Oncohematological Italian Population" Cancers 16, no. 19: 3419.
https://doi.org/10.3390/cancers16193419
APA Style
Urru, S. A. M., Mayer, F., Spila Alegiani, S., Paoloni, F., Guella, A., Murru, R., Bucaneve, G., Formoso, G., Racanelli, V., Ferrarini, I., Fozza, C., Longo, G., Musicco, F., & Campomori, A.
(2024). The Importance of Real-World Data in Evaluating the Safety of Biosimilars: A Descriptive Study of Clinical Practice in an Oncohematological Italian Population. Cancers, 16(19), 3419.
https://doi.org/10.3390/cancers16193419
